Colitis, Ulcerative, Crohn's Disease
Conditions
Keywords
Inflammatory Bowel Disease
Brief summary
Individuals with IBD are at risk for nutrient deficiencies. This prospective, non-randomized, open-label study will assess the effect of a nutrition support product on nutritional status in adults with IBD. Up to ten adults with ulcerative colitis or Crohn's disease will be enrolled in the study and asked to take the product for 12 weeks. The primary measures of the study are several blood markers of nutritional status.
Detailed description
It is estimated that 1-1.3 million people in the United States suffer from the Inflammatory Bowel Diseases (IBD) Crohn's disease (CD) and Ulcerative colitis (UC). The pathophysiology of IBD involves malnutrition, malabsorption, altered intestinal permeability, inflammation, and gut flora alterations. Individuals with IBD are at risk for nutrient deficiencies due to decreased intake, decreased absorption and/or increased enteral losses. The most common deficiencies involve many micronutrients including vitamins and minerals; less commonly, adults may also be at risk for macronutrient deficiencies involving protein and total energy intake. The product being studied is a comprehensive nutrition support product that was formulated to meet the nutritional needs of individuals with digestive complaints. This study will assess the effect of the study product on blood markers of nutritional status in adults with IBD.
Interventions
Nutrition support product contains macronutrients, micronutrients, phytonutrients, prebiotics, and glutamine. Product is in powder form and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
Sponsors
National University of Natural Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Age 18-70 * Ulcerative colitis or Crohn's disease (currently active/not considered in remission) * Willing to have blood drawn twice and willing to fast for 10-12 hours before blood draws * Able to speak, read and understand English
Exclusion criteria
* Currently taking a nutrition support product (macronutrient/micronutrient support product consumed as a reconstituted beverage) or was taken within the last 28 days * Currently receiving intravenous nutrition support therapy (or within the last 28 days) * Currently taking curcumin, turmeric, fenugreek, hops, rosemary, ginger or quercetin (or they were taken within the last 14 days) * Currently taking anti-coagulant or anti-platelet prescription medications (or they were taken within the last 28 days) * Currently taking antibiotic, antiparasitic, or antifungal medications orally or intravenously (or they were taken within the last 28 days) * Initiation of or changes to supplements or medications within 28 days prior to screening * Initiation of or changes to an exercise regimen within 28 days prior to screening * Initiation of or changes to a food plan within 28 days prior to screening * Current involvement or within 28 days prior to screening of a significant diet or weight loss program * Hospitalization (for any reason other than a scheduled medical procedure) within 3 months prior to screening * Gastrointestinal surgery within 3 months prior to screening * Currently have a colostomy or ileostomy bag in place * Malignancy within the last 5 years (with the exception of basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ of the cervix) * Women who are lactating, pregnant or planning pregnancy within the next four months * Difficulty or aversion to taking powdered drink mixes or nutritional shakes * Currently participating in another interventional research study or participated in another interventional study within the previous 28 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall nutritional status | Baseline, 12 weeks | The effect on overall nutritional status will be determined by aggregating data from multiple measures (albumin, red blood cell count, hemoglobin, hematocrit, vitamin B12, folate, sodium, potassium and calcium) into one reported value. The proportion (percentage) of abnormal values present at baseline will be calculated and compared to the proportion of abnormal values present at the end of the study. Mean change, pre-to-post treatment, will also be assessed for each individual measure. |
| Albumin, serum | Baseline, 12 weeks | Mean change, pre-to-post treatment, will be assessed. |
| Red blood cell count | Baseline, 12 weeks | Mean change, pre-to-post treatment, will be assessed. |
| Hemoglobin | Baseline, 12 weeks | Mean change, pre-to-post treatment, will be assessed. |
| Hematocrit | Baseline, 12 weeks | Mean change, pre-to-post treatment, will be assessed. |
| Vitamin B12, serum | Baseline, 12 weeks | Mean change, pre-to-post treatment, will be assessed. |
| Folate, serum | Baseline, 12 weeks | Mean change, pre-to-post treatment, will be assessed. |
| Sodium, serum | Baseline, 12 weeks | Mean change, pre-to-post treatment, will be assessed. |
| Potassium, serum | Baseline, 12 weeks | Mean change, pre-to-post treatment, will be assessed. |
| Calcium, serum | Baseline, 12 weeks | Mean change, pre-to-post treatment, will be assessed. |
Countries
United States
Outcome results
None listed